Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068250 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00068250 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 60 participants.
The verdict
NCT00068250, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining methotrexate, temozolomide, and rituximab with radiation therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide when given together with methotrexate and rituximab followed by radiation therapy and to see how well they work in treating patients with primary central nervous system lymphoma.
Interventions
- DRUG rituximab
- DRUG methotrexate
- DRUG temozolomide 100 mg/m^2
- DRUG temozolomide 150 mg/m^2
- DRUG temozolomide 200 mg/m^2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068250
The ClinicalTrials.gov registry entry for NCT00068250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which rituximab is the first listed.
NCT00068250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068250 about?
NCT00068250 is a clinical study titled "Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma". RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without har...
What is the current status of trial NCT00068250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2003-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00068250?
The interventions under investigation include: rituximab (DRUG), methotrexate (DRUG), temozolomide 100 mg/m^2 (DRUG), temozolomide 150 mg/m^2 (DRUG), temozolomide 200 mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT00068250?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.